Drug approved for condition causing extreme hunger

The American biotech company Rhythm Pharmaceuticals has received FDA approval for the drug Imcivree, containing the active substance setmelanotide, for the treatment of acquired hypothalamic obesity.

The condition is caused by damage to the hypothalamus and results in substantial and persistent weight gain, often combined with extreme hunger. Such damage may, for example, occur in connection with surgery to remove a tumor.